Anti-osteoporotic medications: Traditional and nontraditional

Clinical Obstetrics and Gynecology

Volumn 46, Issue 2, 2003, Pages 341-348

  Cohen, David P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BERBERINE; BISPHOSPHONIC ACID DERIVATIVE; BU ZHONG YI QI TANG; CALCITONIN; CALCITRIOL; CLOMIFENE CITRATE; ESTROGEN; FLUORIDE SODIUM; IPRIFLAVONE; PARATHYROID HORMONE; PHYTOESTROGEN; RALOXIFENE; SAFFLOWER OIL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; STATIN; TIBOLONE;

ALZHEIMER DISEASE; BREAST CANCER; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HERBAL MEDICINE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW;

DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOTHERAPY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0038149580     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200306000-00012     Document Type: Review

References (29)

1. Stini WA. Osteoporosis in biocultural perspective. Ann Rev Anthropol. 1995;24:397-421.
2. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
3. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol. 2003;23:11-16.
4. Thal LJ, Thomas RG, Mulnard R, et al. Estrogen levels do not correlate with improvement in cognition. Arch Neurol. 2003;60:209-212.
5. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med. 2002;113:543-548.
6. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer. 2002;95:1817-1826.
7. Sassa S, Sakamoto S, Zhou YF, et al. Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats. In Vivo. 2001;15:25-28.
8. Sakamoto S, Sassa S, Kudo H, et al. Preventive effects of a herbal medicine on bone loss in rats treated with a GnRH agonist. Eur J Endocrinol. 2000;143:139-142.
9. Hidaka S, Okamoto Y, Yamada Y, et al. A Japanese herbal medicine, Chujo-to, has a beneficial effect on osteoporosis in rats. Phytother Res. 1999;13:14-19.
10. Li H, Miyahara T, Tezuka Y, et al. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull. 1999;22:391-396.
11. Kim HJ, Bae YC, Park RW, et al. Bone-protecting effect of safflower seeds in ovariectomized rats. Calcif Tissue Int. 2002;71:88-94.
12. Yuk TH, Kang JH, Lee SR, et al. Inhibitory effect of Carthamus tinctorius L. seed extracts on bone resorption mediated by tyrosine kinase, COX-2 (cyclooxygenase) and PG (prostaglandin) E2. Am J Chin Med. 2002;30:95-108.
13. Sawyer T, Boyce B, Dalgamo D, Iuliucci J. Src inhibitors: genomics to therapeutics. Expert Opin Investig Drugs. 2001;10:1327-1344.
14. Morelli V, Naquin C. Alternative therapies for traditional disease states: menopause. Am Fam Physician. 2002;66:129-134.
15. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998;338:485-492.
16. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab. 2000;85:1492-1497.
17. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000;85:720-726.
18. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int. 2000;67:286-290.
19. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:875-883.
20. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002;77:1044-1052.
21. Palomba S, Orio F Jr, Morelli M, et al. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab. 2002;87:4476-4481.
22. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
23. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
24. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
25. Tsai KS, Yen ML, Pan HA, et al. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporosis Int. 2001;12:1020-1025.
26. Voss S, Quail D, Dawson A, et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. Br J Obstet Gynaecol. 2002;109:874-885.
27. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985-992.
28. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783-1788.
29. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of agerelated bone loss. J Clin Endocrinol Metab. 2001;86:3618-3628.